Efficacy and Tolerance of the Association of ANIFROLUMAB (300mg) IV Every Four Weeks and Phototherapy Versus Phototherapy in Adults With Progressive Vitiligo

NCT05917561 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

48

Enrollment

OTHER

Sponsor class

Conditions

Vitiligo

Interventions

DRUG: Anifrolumab Infusion Product
DRUG: Placebo

Sponsor

University Hospital, Bordeaux

Collaborators

[object Object]